InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.54
(
-0.19%
)
Bitcoin
65,152.33
(
0.30%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 89689

Wednesday, 01/27/2010 7:03:32 AM

Wednesday, January 27, 2010 7:03:32 AM

Post# of 252255
UTHR/Tadalafil (Adcirca ) patents:

[Adcirca] orphan drug exclusivity in PAH, which can’t be overturned by a P-IV challenge, runs until Apr 2016.

Correct, plus it should get 6-month pediatric extension.

Knocking out the Adcirca CoM patent, which expires in Nov 2017, won’t provide much economic benefit to the P-IV challenger.

I tend to think the challenger is attacking the other 2 patents, which are not as strong as the CoM and run until 2020.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up